IGLL1: A Protein Implicated in Disease and Cancer (G3543)

Target Name: IGLL1

NCBI ID: G3543

IGLL1

IGLL1: A Protein Implicated in Disease and Cancer

IGLL1 (Insulin-like growth factor 1) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cellular growth and has been implicated in the development and progression of many diseases, including obesity, type 2 diabetes, and cancer. In recent years, researchers have been interested in investigating the potential drug targets and biomarkers for IGLL1, with the hope of developing new treatments for these diseases.

One of the main goals of research into IGLL1 is to identify its role in the development and progression of diseases. IGLL1 has been shown to be involved in the regulation of cellular processes that are critical for cancer growth, such as cell division, angiogenesis (the formation of new blood vessels), and invasion. It has also been implicated in the regulation of cellular responses to stimuli, such as the effects of drugs on cell growth and differentiation.

In addition to its role in disease, IGLL1 has also been identified as a potential drug target. Researchers have been investigating the use of drugs that target IGLL1 in order to treat various diseases, including obesity, type 2 diabetes, and cancer. One of the main advantages of targeting IGLL1 with drugs is that it can be a highly effective treatment for diseases that are difficult to treat with traditional approaches. For example, IGLL1 has been shown to be involved in the regulation of cellular responses to pain, which could make it a promising target for the treatment of chronic pain.

Another promising aspect of IGLL1 research is its potential as a biomarker. IGLL1 has been shown to be involved in the regulation of many cellular processes that are important for disease development and progression. Therefore, it may be a useful biomarker for the diagnosis and prognosis of various diseases. For example, IGLL1 has been shown to be involved in the regulation of insulin sensitivity, which could make it a useful biomarker for the diagnosis and treatment of type 2 diabetes.

In conclusion, IGLL1 is a protein that has been shown to be involved in the regulation of many cellular processes that are important for disease development and progression. As a result, it has emerged as a promising drug target and biomarker for the treatment of various diseases. Further research is needed to fully understand the role of IGLL1 in disease and to develop new treatments based on its properties.

Protein Name: Immunoglobulin Lambda Like Polypeptide 1

Functions: Critical for B-cell development

The "IGLL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets